| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |